Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) was up 4.7% during mid-day trading on Tuesday . The stock traded as high as $0.5382 and last traded at $0.50. 4,912 shares changed hands during trading, a decline of 28% from the average daily volume of 6,836 shares. The stock had previously closed at $0.4776.
Avenue Therapeutics Stock Performance
The firm has a market capitalization of $1.65 million, a P/E ratio of 0.03 and a beta of -0.18. The business has a fifty day moving average of $0.40 and a 200-day moving average of $0.37.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for acute pain and other central nervous system conditions. The company is a subsidiary of Fortress Biotech, Inc and has historically concentrated its efforts on hospital-based treatments that address unmet medical needs.
Avenue’s lead product candidate is an intravenous formulation of tramadol intended to manage acute postoperative pain in adults who require an opioid analgesic.
Further Reading
- Five stocks we like better than Avenue Therapeutics
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
